Cargando…

Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations

As nonadherence to antihypertensive drugs (AHDs) can increase the risk of cardiovascular events, hospitalization, and higher costs, there is a need for a reliable, objective, and easy method to assess nonadherence in patients. The dried blood spot (DBS) sampling method used to measure drug concentra...

Descripción completa

Detalles Bibliográficos
Autores principales: Peeters, Laura E. J., Bahmany, Soma, Dekker, Tim, Aliawi, Aya, van Domburg, Bart, Versmissen, Jorie, Koch, Birgit C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275854/
https://www.ncbi.nlm.nih.gov/pubmed/35383727
http://dx.doi.org/10.1097/FTD.0000000000000984
_version_ 1784745578427580416
author Peeters, Laura E. J.
Bahmany, Soma
Dekker, Tim
Aliawi, Aya
van Domburg, Bart
Versmissen, Jorie
Koch, Birgit C. P.
author_facet Peeters, Laura E. J.
Bahmany, Soma
Dekker, Tim
Aliawi, Aya
van Domburg, Bart
Versmissen, Jorie
Koch, Birgit C. P.
author_sort Peeters, Laura E. J.
collection PubMed
description As nonadherence to antihypertensive drugs (AHDs) can increase the risk of cardiovascular events, hospitalization, and higher costs, there is a need for a reliable, objective, and easy method to assess nonadherence in patients. The dried blood spot (DBS) sampling method used to measure drug concentrations meets these requirements. For detecting nonadherence, identification is more important than quantification. Owing to their use in clinical practice, it is important to measure multiple AHDs with a single method. Therefore, we developed and validated a single DBS method for 17 commonly used AHDs and 4 active metabolites using ultrahigh performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS). METHODS: Analytical validation of the DBS assay was performed in accordance with the guidelines on bioanalytical method validation of the European Medicines Agency and US Food and Drug Administration as well as the International Association of Therapeutic Drug Monitoring and Clinical Toxicology guidelines. RESULTS: We validated 12 of the 17 AHDs according to the European Medicines Agency and Food and Drug Administration requirements for bioanalytical method validation. Eleven AHDs were validated for both identification and quantification of drug concentrations, whereas nifedipine was only validated for identification. However, 5 of the 17 AHDs were excluded due to suboptimal validation results. Lercanidipine was excluded due to nonlinearity, and all 4 AHDs measured in the negative mode of UHPLC-MS/MS were not in accordance with one or more of the acceptance criteria and were therefore excluded. CONCLUSIONS: The described method accurately measured AHDs in DBS and can be used to determine nonadherence in patients. However, method validation revealed a challenging balance between analytical limitations and clinical needs when analyzing multiple drugs using the same method.
format Online
Article
Text
id pubmed-9275854
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Therapeutic Drug Monitoring
record_format MEDLINE/PubMed
spelling pubmed-92758542022-08-02 Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations Peeters, Laura E. J. Bahmany, Soma Dekker, Tim Aliawi, Aya van Domburg, Bart Versmissen, Jorie Koch, Birgit C. P. Ther Drug Monit Original Article As nonadherence to antihypertensive drugs (AHDs) can increase the risk of cardiovascular events, hospitalization, and higher costs, there is a need for a reliable, objective, and easy method to assess nonadherence in patients. The dried blood spot (DBS) sampling method used to measure drug concentrations meets these requirements. For detecting nonadherence, identification is more important than quantification. Owing to their use in clinical practice, it is important to measure multiple AHDs with a single method. Therefore, we developed and validated a single DBS method for 17 commonly used AHDs and 4 active metabolites using ultrahigh performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS). METHODS: Analytical validation of the DBS assay was performed in accordance with the guidelines on bioanalytical method validation of the European Medicines Agency and US Food and Drug Administration as well as the International Association of Therapeutic Drug Monitoring and Clinical Toxicology guidelines. RESULTS: We validated 12 of the 17 AHDs according to the European Medicines Agency and Food and Drug Administration requirements for bioanalytical method validation. Eleven AHDs were validated for both identification and quantification of drug concentrations, whereas nifedipine was only validated for identification. However, 5 of the 17 AHDs were excluded due to suboptimal validation results. Lercanidipine was excluded due to nonlinearity, and all 4 AHDs measured in the negative mode of UHPLC-MS/MS were not in accordance with one or more of the acceptance criteria and were therefore excluded. CONCLUSIONS: The described method accurately measured AHDs in DBS and can be used to determine nonadherence in patients. However, method validation revealed a challenging balance between analytical limitations and clinical needs when analyzing multiple drugs using the same method. Therapeutic Drug Monitoring 2022-08 2022-04-05 /pmc/articles/PMC9275854/ /pubmed/35383727 http://dx.doi.org/10.1097/FTD.0000000000000984 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Peeters, Laura E. J.
Bahmany, Soma
Dekker, Tim
Aliawi, Aya
van Domburg, Bart
Versmissen, Jorie
Koch, Birgit C. P.
Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations
title Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations
title_full Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations
title_fullStr Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations
title_full_unstemmed Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations
title_short Development and Validation of a Dried Blood Spot Assay Using UHPLC-MS/MS to Identify and Quantify 12 Antihypertensive Drugs and 4 Active Metabolites: Clinical Needs and Analytical Limitations
title_sort development and validation of a dried blood spot assay using uhplc-ms/ms to identify and quantify 12 antihypertensive drugs and 4 active metabolites: clinical needs and analytical limitations
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275854/
https://www.ncbi.nlm.nih.gov/pubmed/35383727
http://dx.doi.org/10.1097/FTD.0000000000000984
work_keys_str_mv AT peeterslauraej developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations
AT bahmanysoma developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations
AT dekkertim developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations
AT aliawiaya developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations
AT vandomburgbart developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations
AT versmissenjorie developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations
AT kochbirgitcp developmentandvalidationofadriedbloodspotassayusinguhplcmsmstoidentifyandquantify12antihypertensivedrugsand4activemetabolitesclinicalneedsandanalyticallimitations